anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cases of sudden death, QTc interval-prolongation, and Torsades de Pointes have been reported in patients receiving haloperidol (see ADVERSE REACTIONS). Higher than recommended doses of any formulation and intravenous administration of haloperidol appear to be associated with a higher risk of QTc interval-prolongation and Torsades de Pointes. Also, a QTc interval that exceeds 500 msec is associated with an increased risk of Torsades de Pointes. Although cases have been reported even in the absence of predisposing factors, particular caution is advised in treating patients with other QTc-prolonging conditions (including electrolyte imbalance [particularly hypokalemia and hypomagnesemia], drugs known to prolong QTc, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome). HALOPERIDOL DECANOATE MUST NOT BE ADMINISTERED INTRAVENOUSLY. 

Tachycardia and hypotension (including orthostatic hypotension) have also been reported in occasional patients (see ADVERSE REACTIONS). 

Cerebrovascular Adverse Reactions 

In controlled trials, elderly patients with dementia-related psychosis treated with some antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for haloperidol decanoate, other antipsychotics, or other patient populations. Haloperidol decanoate should be used with caution in patients with risk factors for cerebrovascular adverse reactions.
Our study will include individuals who volunteer to participate in the study, and informed consent will be obtained from the individuals. Shoulder protraction will be determined according to the measurement result of the distance between the posterolateral side of the acromion and the bed in the supine position of the individual. If the distance is 2.6 centimeters or more, it will be recorded as shoulder protraction posture. PM length, PM index, upward rotation angle of the scapula at 0°, 45°, 90° and 135° abduction, electromyographic (EMG) muscle activation of the upper trapezius, middle trapezius, lower trapezius and serratus anterior muscles will be evaluated by a blind evaluator before and after the stretching methods. Unilateral corner stretching, manual stretching and proprioceptive neuromuscular facilitation (PNF) stretching methods will be applied randomly, 48 hours apart. The order of Unilateral Corner Stretching, Manual Stretching and PNF Stretching methods to be applied to individuals will be assigned with the simple allocation using random allocation. SPSS (Statistical Package for Social Sciences) version 22.0 will be used to evaluate the data obtained from the study and create tables. The Shapiro-Wilk test will be used to determine the distribution of the data. Descriptive statistics of numerical variables with normal distribution will be indicated by X ± SD, descriptive statistics of numerical variables without normal distribution will be indicated by median and (IQR), descriptive statistics of categorical variables will be indicated by frequency and percentage (%). Paired Sample T test will be used for intra-group comparison of normally distributed data and Wilcoxon test will be used for intra-group comparison of non-normally distributed data. The one-way repeated measures analysis of variance (ANOVA) will be performed to compare the three groups. The statistical significance level will be set at p\<0.05 and a post-hoc multiple comparisons test with Bonferroni correction will be performed.
Caramelised lactulose is new and consists of lactulose, adjuvants, by-prods. of carmaelisation, and water. It has the same uses as the unaltered disaccharide. It is useful in the treatment of chronic constipation, in the treatment and prophylaxis of ammonia intoxication of the large intestine, esp. in liver cirrhosis with portal hypertension, and in modifying intestinal flora for treating salmonellosis. While being equiactive with crystalline lactulose, caramelised lactulose is a pleasant-tasting material similar to caramelised sucrose and can be administered e.g. in the the form of toffees. The caramelisation process is easier to carry out than the crystallisation of lactulose. In an example, aqueous 50% lactulose is boiled with animal or vegetable fat up to incipient caramelisation, then mixed with milk and further boiled to give a toffee which is poured into bonbon moulds and cooled.
Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension.
<P>PROBLEM TO BE SOLVED: To provide a new CD33-like protein, to provide an isolated nucleic acid molecule which encodes the CD33-like protein, to provide a recombinant vector containing the nucleic acid molecule, and to provide a host cell formed by being immunologically treated with the recombinant vector.  <P>SOLUTION: This isolated nucleic acid molecule contains a nucleic acid molecule having a specific sequence which encodes the CD33-like protein or a polypeptide fragment of the protein. The recombinant vector contains the nucleic acid molecule. The host cell is formed by being genetically treated with the recombinant vector. The CD33-like protein or the polypeptide fragment is produced by a recombination technique in the host cell.  <P>COPYRIGHT: (C)2004,JPO
All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
PURPOSE OF REVIEW: Gout flares are a paramount component of disease burden inflicted by gout onto the patient. Furthermore, they are included in the core domain set for long-term gout studies recognized by Outcome Measures in Rheumatology. Along with a validated classification criterion for gout, gout investigators have turned their efforts into defining and characterizing the gout flare. This brief review will summarize the efforts that have been done to define and characterize a gout flare in clinical studies.
RECENT FINDINGS: Recent findings include a validated definition of a gout flare that has been utilized in novel clinical studies, use of technology to monitor for gout flares and their effects on patient life, and qualitative analyses into the disease burden that a patient undergoes.
SUMMARY: Although guidelines for core outcome domains have been well established, there is question in methods of measuring and reporting gout flares in long-term trials. Furthermore, there is question as to the effectiveness of the agreed upon instruments' abilities to fully capture the disease burden experienced by patients with gout. A combination of outcome measurements including binary data (gout flare present or absent) along with a comprehensive measurement of disease burden over time would theoretically provide a more accurate description of the disease and serve as a basis for intervention development.
On Day 1 of the treatment period, patients will undergo standard-of-care diagnostic laparoscopy to confirm the absence of metastatic disease not seen on staging imaging, as well as tissue acquisition (blood and liver biopsies) for pre-specified correlative scientific studies. On Day 2 (±1 day), patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy. On Day 14 (±5 business days), patients will undergo standard-of-care resection of their primary tumor, as well as tissue acquisition (blood, liver biopsies, primary tumor, regional lymph nodes) for pre-specified correlative scientific studies.
In recent times, the focus on collecting patient-reported outcomes (PROs) has increased in healthcare. The Food and Drug Administration defines PROs as a -measurement of any aspect of a health status of the patient that comes directly from the patient-. These includes disease symptoms, functional aspects and quality of life (QOL). The collection of PROs, combined with physician-assessed toxicity, is constantly being incorporated into clinical practice and studies to provide a more holistic picture of the impact of treatment on patients and prove useful for planning future interventions. Although the use of PROs has now become the standard for measuring quality of life of patients there are still few studies on the self-reported long-term QOL of anal cancer patients and on disease or therapy related symptoms that affect QOL. Therefore, the EORTC (European Organisation for Research and Treatment of Cancer) has recently developed the specific Quality of Life Questionnaire for anal cancer (QLQ-AN27) module to explore typical symptoms of anal cancer and its therapy. In this study, the QLQ-AN27 questionnaire will be administered together with the EORTC Quality of Life 30 (QLQ 30) in patients with anal cancer who have undergone radio-chemotherapy. The questionnaire may be administered before treatment, after treatment and during follow-ups until completion of the fifth year. This is an observational study both retrospective and prospective.
Background: There is an insufficient understanding of factors that impede nursing students' learning of healthcare-associated infection prevention and control in developing countries. This study aimed to explore current challenges in healthcare-associated infection control and prevention education in the nursing curriculum in two Vietnamese and two Cambodian universities. Methods: Exploratory research was conducted through consultation of education programs and a qualitative study design utilizing interviews and focus group discussions. Data collection was conducted through interviews with university board members and focus group discussions with lecturers and tutors. The data were analyzed by using content analysis methods. Results: The research results indicated that there were three generic themes of challenges in teaching HAIs-PC in nursing education in Vietnam and Cambodia. They were Implementation of healthcare associated infections prevention and control education into nursing curriculum, Positive aspects fostering healthcare associated infections prevention and control learning, Negative aspects hindering healthcare associated infections prevention and control learning. Conclusions: The study results provided evidence of challenges in healthcare associated infections prevention and control education in some Asia higher education institutions. To improve professional safety, universities should pay more attention to developing appropriate teaching methods for healthcare-associated infections prevention and control education to improve students' practice outcomes.
All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
BACKGROUND: The anterior quadratus lumborum (QL) block may be used for postoperative pain management for intra-abdominal surgeries, but the evidence is uncertain. We aimed to investigate the benefit and harm of the anterior QL block compared to placebo/no block for intra-abdominal surgery.
METHODS: We searched Medline, Embase, and CENTRAL for randomized controlled trials investigating anterior QL block for postoperative pain management for adult patients undergoing any intra-abdominal surgery. The two co-primary outcomes were cumulative 24-h opioid consumption and serious adverse events. We performed meta-analysis, trial sequential analysis (TSA), assessed the risk of bias, and present the certainty of evidence with the Grading of Recommendations, Assessment, Development and Evaluation approach.
RESULTS: Thirty-five trials randomizing 2418 patients were included in the meta-analyses. Anterior QL block may reduce cumulative 24-h intravenous opioid consumption compared to placebo/no block (MD -10.42 mg, 96.7% CI -14.83 to -6.01, TSA-adjusted CI -17.03 to -3.82, p < .01). Two trials reported on SAEs. Anterior QL block may have little to no effect on the number of serious adverse events compared to placebo (RR 1.49, 96.7% CI 0.19 to 11.47, p = .68), but the evidence is very uncertain. All trial results were assessed as being high risk of bias.
CONCLUSIONS: The anterior QL block may reduce cumulative 24-h opioid consumption. Reported serious adverse events were few and the anterior QL block may have little to no effect on the number of SAEs, but the evidence was very uncertain.
This is a Phase III, monocentric, prospective trial in which patients will be randomized to AR RARP vs. standard approach (standard RARP). Patient population is defined as: patients≥18 years old, untreated biopsy-proven adenocarcinoma of the prostate classified as European Association of Urology (EAU) low or intermediate risk (PSA≤20 ng/ml and cT≤2b and International Society for Urological Pathology \[ISUP\] grade group≤III), pre-operative International Index of Erectile Function-5 (IIEF-5)≥20, no contraindications for multiparametric magnetic resonance imaging (mpMRI). The primary objective of this study is to compare the rates of PSMs with AR RARP vs. standard RARP. Secondary objectives are the rates of nerve sparing approaches and erectile function recovery at 3-, 6- and 12-months after surgery in AR RARP vs. standard RARP. Subgroup analyses will tested for a specific subgroup of patients in which AR RARP should be particularly indicated. Longer-term follow-up will also assess the percentages of biochemical recurrences (BCR) in the two groups.
BACKGROUND This prospective study aimed to compare outcomes and hearing improvement in 51 patients with adhesive otitis media following endoscopic and microscopic tympanoplasty. MATERIAL AND METHODS Between April 2021 and April 2022, 51 patients diagnosed with pars tensa retraction and hearing loss who underwent endoscopic and microscopic cartilage tympanoplasty were included in the study (endoscopic tympanoplasty group: 26 patients, microscopic tympanoplasty group: 25 patients). Pure-tone audiometric data (0.5, 1, 2, and 4 kHz), air-bone gap (ABG), and postoperative graft intake were compared. RESULTS Hearing gain in the ABG was significant in both groups (p<0.05). When the groups were compared for mean hearing gain in the ABG, the difference was significant (p<0.05). The postoperative ABG in the endoscopic group was significantly smaller than that in the microscopic group. When the postoperative air conduction threshold was evaluated, there was no significant difference between the 2 groups at 4 kHz, whereas a significant difference was observed in the endoscopic tympanoplasty group at 0.5, 1, and 2 kHz. Postoperative graft failure and otorrhea were not observed in any of the patients. CONCLUSIONS Pars tensa retractions and adhesive otitis media show comparable outcomes with both endoscopic and microscopic techniques. In endoscopic tympanoplasty, better visualization allows for better hearing outcomes. The endoscopic method, characterized by a wide field of view and a less invasive approach, enhances access to retraction limits.
The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.
The invention relates to a process and a device for preserving extracts (primary extracts) produced from Serenoa repens fruits. The preservation is carried out by treating the primary extracts in a high-pressure column with zones at various temperatures in the horizontal and vertical direction. A fractional extraction and deposition thus takes place in the column. The capric and caprylic acids which reduce the stability, and the unwanted odour and taste substances in the primary extract, are removed in a deposition vessel located outside the column. The secondary extracts obtained after the fractional extraction in the column can be kept for considerably longer than the starting materials used and are suitable as active substances for pharmaceutical and cosmetic purposes. <IMAGE>
Approximately 30 individuals whose loved ones are experiencing FEP and receiving services from two of the five FEP clinics (OASIS and SHORE) will be recruited to participate in a digital platform, Altitudes, for 6 months as part of an adjunct service to the clinic's services. Participants will have access to and encouraged to use the educational and therapeutic content as well as the moderated online community network during their time engaging with the platform. They will be asked to complete a battery of measures at baseline, 3-months, and 6 months.
Method of making methyl resorcinol comprises (a) contacting toluene diamine with ammonium bisulphate in an aq. soln. contg. 4-12 moles of ammonium bisulphate per mole of toluene diamine and 40-120 moles of water per mole of toluene diame at 200-300 degrees C for 0.5-8 hrs. to hydrolyse the toluene diamine to methyl resorcinol, (b) cooling the reaction mixture and (c) extracting the methyl resorcinol from the soln. with a water-immiscible organic solvent. Methyl resorcinols have mild germicidal and antiseptic properties and find use in skin lotions and hair tonics.
PURPOSE: A pharmaceutical composition containing an Acorus gramineus Soland extract for preventing and treating erectile dysfunction(ED) is provided to basically treat vascular condition without side effects by continuously administering, and to prevent, treat, and alleviate erectile dysfunction. CONSTITUTION: A pharmaceutical composition for preventing and treating erectile dysfunctional contains an Acorus gramineus Soland extract as an active ingredient. The extract is prepared using ethanol. The extract relaxes smooth muscle of corpus cavernosum penis through NO-cGMP pathway. The extract causes hyperpolarization by opening K+ pathway and relaxes smooth muscle of corpus cavernosum penis. A health functional food composition contains a sitologically acceptable food additive and the extract.
This is a randomized (study drug assigned by chance), double-blind (neither the investigator or patient will know the identity of the assigned treatment) to compare the overall survival of patients with advanced pancreatic cancer after treatment with gemcitabine with and without tipifarnib (referred to as R115777). Gemcitabine is an approved chemotherapy agent administered intravenously (iv) (though a vein) for patients with advanced pancreatic cancer. R115777 is an orally (by mouth) administered investigational drug that is being tested in combination with gemcitabine for the treatment of patients with advanced pancreatic cancer. Patients will continue to receive treatment with gemcitabine and R115777 (or placebo) unless disease progression or unacceptable toxicity is observed. All patients in the study will be followed for study assessments and safety for up to the 5 years, the start of further treatment, or death (whichever comes first). R115777 (or matching placebo) 200 mg will be orally administered at intervals of approximately 12 hours daily throughout the study. Gemcitabine will be administered iv at a starting dose of 1000 mg/m2 every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter. Treatment with gemcitabine and tipifarnib (or placebo) will continue for up to 5 years (or until the start of further treatment) in the absence of disease progression or unacceptable toxicity.
Embodiments relate to a medical information processing apparatus, a medical information processing system, and a medical information processing method. The purpose is to achieve an improvement in inspection efficiency. The medical information processing device according to the embodiment includes a reception unit, a setting unit, and a command control unit. The receiving unit receives, for each of a plurality of tests for diagnosing a disease assumed for a subject, 1 st information indicating whether or not a doctor's confirmation is required before the execution, and 2 nd information indicating whether or not the subject or an appropriate agent's agreement is required before the execution. The setting unit sets the 1 st information and the 2 nd information as incidental information for each of the plurality of checks. The instruction control unit controls an inspection instruction including the plurality of inspections based on the incidental information.
PROBLEM TO BE SOLVED: To obtain a powder cosmetic excellent in effect capable of covering structural defect of skin, e.g. pores of the skin, rough texture or fine wrinkles by combining specific powder capable of realizing uniform adhesion state with a specific component having high affinity for skin. SOLUTION: This powder cosmetic is obtained by combinedly using (A) modified powder (in an amount of 0.5-30wt.%) obtained by subjecting the surface of mixed powder of fine powder having 0.001-0.1μm average primary particle diameter with laminar powder to uniform coating treatment with an acylated amino acid and (B) a polyhydric alcohol (in an amount of 0.2-10wt.%). The fine particle powder of the component A includes e.g. fine particle titanium oxide and the laminar powder includes e.g. barium sulfate, etc., and the acylated amino acid includes e.g. N-lauroyl-L-lysine. The component B includes e.g. propylene glycol. The powder costemic has good slip on skin and is free from messy makeup with the passage of time.
The application discloses a composition containing natural Chinese herbal medicines for removing freckles and whitening and application of the composition in cosmetics. The application fully plays roles of the natural Chinese herbal medicine related antioxidant, freckle removing and vascular active ingredient activating, but most of the natural Chinese herbal medicine active ingredients are relatively poor in water solubility and fat solubility and are difficult to absorb by skin. Therefore, the invention utilizes the liposome to prepare the nano microsphere loaded with mung bean, rhododendron leaf tea, chinese angelica natural extract and walnut cake polypeptide. The prepared nano microsphere can penetrate through skin, so that the effective components in the nano microsphere are better absorbed by the skin. The Chinese herbal medicine components form a synergistic effect, so that the freckle removing and whitening effects of the composition are enhanced. In addition, the sample prepared by the invention has anti-inflammatory effect, and promotes the formation of fibroblasts, thereby achieving the effect of treating skin burn.